Company intelligence / Profile preview

Grace Lifetech

Hangzhou, Zhejiang, China

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Grace Lifetech is a clinical-stage biotechnology company focused on developing innovative gene therapies using its proprietary AAV-S platform. The company specializes in engineering next-generation adeno-associated virus (AAV) vectors to improve delivery efficiency and safety across various therapeutic areas. Its lead program, GL-001, is currently being evaluated in clinical trials for the treatment of wet age-related macular degeneration (wAMD). Grace Lifetech's pipeline also includes candidates for diabetic macular edema and central nervous system disorders. By leveraging its high-throughput capsid screening technology, the company aims to address unmet medical needs with durable, single-administration genetic medicines.

Therapeutic areas: NeurologyOphthalmology
Modalities: Gene therapyAAV
Industry: Biotech

Beyond the preview

Go deeper on Grace Lifetech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Grace Lifetech.

Explore the full profile